We’re thrilled to share a recent publication on Siranomics, Inc. and Sagesse Bio's siRNA injectable when used for targeted local fat reduction. Results yielded positive results showing a notable decrease in adipocyte volume and lipid content. Read more below!
Sagesse Bio’s Post
More Relevant Posts
-
📢 Attention researchers! Invitrogen™ Vivofectamine™ Delivery Solutions have arrived to revolutionize in vivo delivery of nucleic acids with lipid nanoparticles (LNPs)! With their outstanding versatility and safety profile, Vivofectamine products are the ideal choice for both basic researchers and therapeutic development. But that's not all – we also offer custom products and services for supporting therapeutic development. From start to finish, our Vivofectamine Delivery Solutions can provide the delivery system you need for success. Don't miss out on the opportunity to enhance your research, accelerate your project timelines and take it to the next level. Check out Vivofectamine now and unlock new possibilities! 🔗 https://lnkd.in/e3cd5Mrk #delivery #lipidnanoparticles #nucleicacidmedicine #mrnavaccine #mrnatherapeutics #vivofectamine #LNP
To view or add a comment, sign in
-
#Thyroid_Function_Test Market Share Charges Ahead with Huge Growth 2023-2032 https://lnkd.in/dtB6UBBT A #thyroid function test is a blood test used to evaluate the #performance of the thyroid gland, a #gland with a butterfly-shaped #structure situated in the #neck. This gland is vital in regulating a #wide range of bodily functions. The thyroid gland #generates hormones, primarily #thyroxine (T4) and #triiodothyronine (T3), which have a #significant influence on metabolism, energy #production, and the proper #operation of various organs and #tissues. Thermo Fisher Scientific Abbott Roche Diasorin Danaher Corporation KRONUS Merck Group Diagnostic Automation / Cortez Diagnostics, Inc. bioMérieux Qualigen Therapeutics Autobio Diagnostics #technologies #marketgrowth #innovationmanagement #healthcareindustry #pharmaceuticalproducts #thyroid #hyperthyroidism
To view or add a comment, sign in
-
Current #hypoparathyroidism treatments require frequent dosing, which can be both inconvenient, and result in wide fluctuations in the bloodstream, potentially impacting efficacy and side effects of the medicine. At MBX Biosciences, patients are at the forefront of our approach to developing new and better medicines to manage hypoparathyroidism (HP). Learn more about how MBX-2109, our investigational long-acting parathyroid hormone (PTH) peptide prodrug, aims to deliver consistent therapeutic benefits while minimizing disruptions to daily life through a once-weekly dosing regimen. #biotechnology
To view or add a comment, sign in
-
#Thyroid_Function_Test Market 2023: Global Industry Analysis, Opportunities and Forecast To 2032 << https://lnkd.in/dtB6UBBT A #thyroid function test is a blood test used to evaluate the #performance of the thyroid gland, a #gland with a butterfly-shaped #structure situated in the #neck. This gland is vital in regulating a #wide range of bodily functions. The thyroid gland #generates hormones, primarily #thyroxine (T4) and #triiodothyronine (T3), which have a #significant influence on metabolism, energy #production, and the proper #operation of various organs and #tissues. Thermo Fisher Scientific Abbott Roche Diasorin Danaher Corporation KRONUS Merck Group Diagnostic Automation / Cortez Diagnostics, Inc. bioMérieux Qualigen Therapeutics Autobio Diagnostics #technologies #marketgrowth #innovationmanagement #healthcareindustry #pharmaceuticalproducts #thyroid #hyperthyroidism
To view or add a comment, sign in
-
Fancy some light reading to ease your way into the weekend? Check out Tamsin Mansley's latest article in IBI Journal for a quick overview of the things you should know about metabolism in drug discovery 📖 https://lnkd.in/eBqBQ9dt #DrugMetabolism #InSilico #Metabolites #DrugDiscovery
To view or add a comment, sign in
-
Check out Gyrolab for oligonucleotide quantification: high throughput, low volume, highly reproducible and sensitive.
Our new In the Zone: oligonucleotide therapy quantitation in partnership with Gyros Protein Technologies is now available! Check out the resources now >>> https://hubs.ly/Q02wNSXZ0
To view or add a comment, sign in
-
Peptide drug discovery is a fascinating field - learn more in our series of posts on this topic > #healthcareinnovation #Peptides #DrugDiscovery
#𝐏𝐞𝐩𝐭𝐢𝐝𝐞𝐬 𝐚𝐧𝐝 #𝐃𝐫𝐮𝐠𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 – 𝐏𝐚𝐫𝐭 1 Peptide drug discovery is a fascinating field. Did you know that the first peptide drug was insulin, isolated and purified from bovine pancreases to treat diabetes nearly a hundred years ago!? Though this process constituted a massive scientific and medical breakthrough, it was costly, inefficient, and limited to peptide hormones found naturally in the body. This led researchers to seek a better way to provide patients with much needed peptides. So what happened next? Tune in for our next post! #healthcareinnovation
To view or add a comment, sign in
-
Pre-clinical data supporting the potential of INZ-701, Inozyme Pharma's lead ENPP1 enzyme replacement therapy (ERT) development candidate, to treat a broad range of diseases mediated by the PPi-Adenosine Pathway, was recently published in the journal Cells. The PPi-Adenosine Pathway is critical for regulating bone health and blood vessel function. The ENPP1 enzyme is a vital component of this pathway and plays an essential role in generating inorganic pyrophosphate (PPi), a key regulator of mineralization, and adenosine, a key regulator of intimal proliferation. INZ-701 is designed to increase PPi and adenosine, addressing deficiencies in these molecules and offering the potential to treat multiple rare diseases driven by disruptions in the PPi-Adenosine Pathway. Read the data: https://lnkd.in/eJ2HjEia #biotech
To view or add a comment, sign in
-
Milk exosomes (mExos) have been demonstrated as oral delivery vehicles for protein and peptide drugs due to their superior ability to cross the epithelial barrier. However, certain challenges remain due to their intrinsic characteristics, including suboptimal drug loading efficiency, insufficient mucus penetration, and susceptibility to membrane protein loss. Here, researchers introduce a hybrid vesicle (mExos@DSPE-Hyd-PMPC) with adaptive surface properties, designed by fusing functionalized liposomes with native mExos, aiming to overcome the limitations associated with mExos and unleash their full potential in oral peptide delivery. https://lnkd.in/gwdzfGrG
To view or add a comment, sign in
-
#𝐏𝐞𝐩𝐭𝐢𝐝𝐞𝐬 𝐚𝐧𝐝 #𝐃𝐫𝐮𝐠𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 – 𝐏𝐚𝐫𝐭 1 Peptide drug discovery is a fascinating field. Did you know that the first peptide drug was insulin, isolated and purified from bovine pancreases to treat diabetes nearly a hundred years ago!? Though this process constituted a massive scientific and medical breakthrough, it was costly, inefficient, and limited to peptide hormones found naturally in the body. This led researchers to seek a better way to provide patients with much needed peptides. So what happened next? Tune in for our next post! #healthcareinnovation
To view or add a comment, sign in
81 followers
Global Leader in Pharmaceuticals, Medical Devices and Biotechnology | Leadership | KOL Development | Marketing | Dermatology and Vision Care | Launch Excellence
2moGreat news and hopefully first of many to come! Thanks Dr. Nestor and team for all of the strong work here.